DISCOVERING AND DEVELOPING SAFE AND EFFECTIVE THERAPIES FOR SIGHT-THREATENING EYE DISEASES

Naegis is driven to create new therapies for serious eye diseases that are leading causes of blindness

Building on its expertise in anti-inflammatory drug discovery, the company has designed and produced a series of compounds that have the potential to be beneficial in the treatment of serious eye diseases, including those that affect the back of the eye, through delivery to the retina by an eye drop.

icon INFLAMMATORY EYE DISEASES

Inflammatory eye diseases may result in damage of eye tissue, leading to reduced vision and/or vision loss.

icon OUR TECHNOLOGY

Designing small molecules that block pro-inflammatory mediators in disease.

What we do

Chronic inflammatory disease represents an enormous societal and economic burden, particularly in an aging population, impacting both quality and quantity of life. Naegis Pharmaceuticals Inc. is driven to discover new therapies that target underlying chronic inflammatory processes in disease. The Naegis research team seeks to design new drugs that offer safer and more effective treatment options for patients, focusing first on serious eye conditions that result in damage to the back of the eye, with a program directed towards blocking the synthesis of pro-inflammatory mediators in disease.  [...]

More

DISCOVERING AND DEVELOPING SAFE AND EFFECTIVE THERAPIES FOR SIGHT-THREATENING EYE DISEASES

Meet Our Team

David Burgoyne, Ph.D.
Founder and CEO
John Langlands, Ph.D.
Vice President Pre-Clinical Research
Dr. Peter Hnik, MD, MHSc
Clinical Advisor



icon
Suite 720, 999 West Broadway Vancouver, B.C. V5Z 1K5
icon
This email address is being protected from spambots. You need JavaScript enabled to view it.
icon
604-235-1682
Top
We use cookies to improve our website. By continuing to use this website, you are giving consent to cookies being used. More details…